Advertisement
12/11/2020

Open Book Extracts unveils private label pet portfolio

David Salazar
Managing Editor
David Salazar profile picture

Open Book Extracts is using its cannabis expertise to offer private label and white label pet products with cannabinoids. The company’s collection spans pet tinctures, soft chews and oral strips that contain the Roxboro, N.C.-based company’s cannabinoid ingredients, including CBD, cannabigerol, or CBG; cannabinol, or CBN, cannabichromene, or CBC; and tetrahydrocannabivarin, or THCV. 

In addition to its cannabinoid isolates, the company, which refers to itself as OBX, also offers THC-free broad-spectrum distillates that can be customized to its clients’ specifications. In addition to tinctures, chews and oral strips, its finished-product portfolio includes soft gels, tablets, and topicals, as well as water-soluble powders and liquids. OBX said its pet products are formulated with the same cannabinoids it uses for all of its other finished products. 

"Animals, like humans, have an endocannabinoid system, or ECS. OBX has developed this pet product portfolio in response to a growing trend among pet owners seeking safe, consistent cannabinoid-based products for their dogs and cats," said Trevor Gentry, OBX senior formulation scientist. "Many use cannabinoids for aging pets to improve mobility and general quality of life, while others use cannabinoids to calm overly anxious, restless, or excitable pets. OBX designed each new pet product with premium, targeted active ingredients along with our [National Animal Supplement Council]-accredited pure cannabinoid ingredients to help pets and pet owners alike find balance and wellness in their day."

Like all of its products, the company said that its products are all tested by a third-party laboratory to validate quality and purity. The move into the pet space looks to gain a share of the burgeoning CBD pet products market, which Nielsen and Headset’s recent 2020 Pet Industry Green Paper said will represent between 3% and 5% of all hemp sales in the United States by 2025. Additionally, Brightfield Group estimates the CBD pet products market could grow to $1.16 billion by 2022. 

"The OBX team has spent countless hours on this new product line, and we believe that our OBX pet products are superior to many of the cannabinoid pet products you may see on the shelf today," says Zach Edge, OBX director of global strategy. "As an NASC-preferred ingredient supplier, OBX is proud to serve the demands of the pet industry. We will continue to expand our white label animal health offerings in the coming months and are excited to work collaboratively with private label customers."

The company’s full pet catalog can be found here